Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACHE01-PRODIGE48 Study
NCT02959879Phase 2Completed
- Sponsor
- Rouen University Hospital
- Start
- Mar 2017
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of FOLFIRINOX and FOLFOX in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Rouen University Hospital. Primary endpoints: Overall Survival at 12 months and Treatment Completion Rate at 12 months. Started Mar 2017; status: completed.
02
Drugs
FOLFIRINOXFOLFOX
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02959879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959879.